Phase II Trial Exploring the Feasibility of Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA Non-Small Cell Lung Cancer
- Evaluate the feasibility of adjuvant carboplatin and docetaxel in patients with
resected stage I, II, or IIIA non-small cell lung cancer.
- Determine the toxicity of this regimen in these patients.
- Determine the survival patterns of patients treated with this regimen.
- Assess the patterns of recurrence in patients treated with this regimen.
OUTLINE: Patients receive carboplatin IV on day 1 and docetaxel IV on day 1. Treatment
repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable
After completion of study treatment, patients are followed every 3 months for 2 years and
then every 6 months for 3 years.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Feasibility of administering of carboplatin/docetaxel as adjuvant therapy in resected stage I-IIIA NSCLC
Mark A. Socinski, MD
UNC Lineberger Comprehensive Cancer Center
United States: Institutional Review Board
|University of North Carolina Lineberger Comprehensive Cancer Center||Chapel Hill, North Carolina 27599|